Yuhan Corporation

000105.KS

000105.KSYuhan Corporation

KSE

138,200.00

KRW

-4,900.00

(-3.42%)

8.75TMarket Cap

Oct 29Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Yuhan Corporation

000105.KS

(KSE)

Recent

price

138,200.00

P/E

ratio

- -

div

yld

0.33%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 09/14

Stock

S&P500

116.28

25.87

129.95

25.85

247.24

86.66

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
7,567.96	7,813.1	8,120.04	8,658.74	10,040.25	12,204.47	13,308.97	14,870.04	18,283.32	20,367.12	20,935.11	3,713.99	20,376.7	22,325.57	22,522.16	24,125.08	19,376.33	Revenue per Share
1,555.78	1,470.61	1,566.34	1,201.07	1,044.5	1,118.27	1,189.61	1,660.56	2,232.11	1,518.7	792.3	100.37	2,424.79	1,356.92	1,206.67	1,247	856.55	Basic EPS, GAAP
1,242.39	1,524.55	1,728.09	731.98	624.45	261.83	731.75	565.96	-145.09	922.28	618.29	48.3	-784.27	226.53	65.32	738.06	-658.44	Free Cash Flow per Basic Share
114.04	116.73	123.81	134.3	170.85	170.7	204.43	237.64	284.4	288.97	302.41	57.48	299.15	329.9	330.75	363.65	427.71	Dividend per Share
8,583.77	9,758.41	11,358.49	13,216.64	14,218.83	15,187.55	16,167.57	17,512.89	20,306.1	21,611.84	21,623.19	3,962.18	22,115.85	24,739.32	25,055.55	26,611.84	- -	Book Value per Share
10,615.95	11,631.7	13,070.39	14,100.61	15,238.94	15,743.61	16,546.02	17,797.22	20,480.18	21,998.99	22,285.22	4,064.54	22,476.87	24,432.78	23,704.39	24,392.99	28,148.79	Tangible Book Value per Share
81	83	82	78	77	77	76	76	72	72	73	399	79	76	79	75	75	Basic Weighted Avg Shares
611,186	646,773	663,570	679,231	776,458	943,609	1,017,492	1,128,731	1,320,797	1,462,248	1,518,823	1,480,354	1,619,865	1,687,810	1,775,847	1,809,082	1,455,969	Sales/Revenue/Turnover
13.58	13.35	12.45	7.38	4.46	6.55	7.31	7.6	7.4	6.07	3.3	0.85	5.2	2.88	2.03	3.16	11.6	Operating Margin (%)
22,906	25,395	21,545	17,777	17,432	18,903	26,513	31,056	42,920	52,195	59,000	58,658	59,785	52,671	43,019	31,671	26,004	Depreciation Expense
125,644	121,738	128,002	94,217	80,776	86,461	90,948	126,047	161,249	109,034	57,481	40,006	192,761	102,583	95,144	93,510	64,362	Net Income, GAAP
13.35	10.95	10.5	11.83	24.54	19.29	21.66	25.13	21.3	24.35	34.74	33.33	20.63	21.37	4.57	4.79	15.91	Effective Tax Rate (%)
20.56	18.82	19.29	13.87	10.4	9.16	8.94	11.17	12.21	7.46	3.78	2.7	11.9	6.08	5.36	5.17	4.42	Profit Margin (%)
316,832	441,508	469,965	472,909	500,493	491,239	586,119	602,752	723,907	793,199	761,249	764,724	813,342	792,118	754,743	681,703	672,276	Working Capital
2,460	1,400	- -	- -	- -	18,500	24,100	86,000	140,250	115,339	70,212	49,656	51,029	32,622	3,402	167	- -	LT Debt
862,596	967,706	1,072,720	1,116,723	1,188,217	1,228,246	1,275,865	1,363,940	1,496,552	1,606,325	1,651,736	1,649,991	1,846,502	1,935,889	2,007,806	1,983,711	2,115,146	Total Equity
8.5	8.26	7.19	4.01	2.24	4	4.41	4.45	4.75	3.87	1.84	0.47	3.58	1.87	1.63	2.65	6.72	Return on Invested Capital (%)
18.99	16.01	14.61	9.54	7.53	7.46	7.3	9.21	10.51	6.67	3.48	2.69	11.07	5.57	5.03	4.64	6.58	Return on Capital (%)
19.82	16.22	14.75	9.59	7.56	7.6	7.55	9.83	11.53	7.22	3.68	2.54	11.55	5.65	4.95	4.71	6.57	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	6.85%	3.63%	1.87%
Net Income, GAAP	28.77%	59.14%	-1.72%
Free Cash Flow	-43.91%	59.24%	974.53%
Total Cash Common Dividend	7.67%	4.45%	4.56%
Total Equity	4.98%	3.83%	-1.2%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

	Dec'23	Mar'24	Jun'24
Total Current Assets	- -	1,244,630	1,320,920
Accounts Receivable, Net	- -	540,835	- -
Cash, Cash Equivalents & STI	- -	297,914	- -
Inventories	- -	301,104	- -
Total Current Liabilities	- -	562,112	648,644
Payables & Accruals	- -	- -	- -
ST Debt	- -	134,938	- -
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	- -	134,938	- -
LT Borrowings	- -	78,651	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	1,181	- -
Shares Outstanding	70	74	74
Market Capitalization	4,852,677	4,880,281	5,147,202

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
7,567.96	7,813.1	8,120.04	8,658.74	10,040.25	12,204.47	13,308.97	14,870.04	18,283.32	20,367.12	20,935.11	3,713.99	20,376.7	22,325.57	22,522.16	24,125.08	19,376.33	Revenue per Share
1,555.78	1,470.61	1,566.34	1,201.07	1,044.5	1,118.27	1,189.61	1,660.56	2,232.11	1,518.7	792.3	100.37	2,424.79	1,356.92	1,206.67	1,247	856.55	Basic EPS, GAAP
1,242.39	1,524.55	1,728.09	731.98	624.45	261.83	731.75	565.96	-145.09	922.28	618.29	48.3	-784.27	226.53	65.32	738.06	-658.44	Free Cash Flow per Basic Share
114.04	116.73	123.81	134.3	170.85	170.7	204.43	237.64	284.4	288.97	302.41	57.48	299.15	329.9	330.75	363.65	427.71	Dividend per Share
8,583.77	9,758.41	11,358.49	13,216.64	14,218.83	15,187.55	16,167.57	17,512.89	20,306.1	21,611.84	21,623.19	3,962.18	22,115.85	24,739.32	25,055.55	26,611.84	- -	Book Value per Share
10,615.95	11,631.7	13,070.39	14,100.61	15,238.94	15,743.61	16,546.02	17,797.22	20,480.18	21,998.99	22,285.22	4,064.54	22,476.87	24,432.78	23,704.39	24,392.99	28,148.79	Tangible Book Value per Share
81	83	82	78	77	77	76	76	72	72	73	399	79	76	79	75	75	Basic Weighted Avg Shares
611,186	646,773	663,570	679,231	776,458	943,609	1,017,492	1,128,731	1,320,797	1,462,248	1,518,823	1,480,354	1,619,865	1,687,810	1,775,847	1,809,082	1,455,969	Sales/Revenue/Turnover
13.58	13.35	12.45	7.38	4.46	6.55	7.31	7.6	7.4	6.07	3.3	0.85	5.2	2.88	2.03	3.16	11.6	Operating Margin (%)
22,906	25,395	21,545	17,777	17,432	18,903	26,513	31,056	42,920	52,195	59,000	58,658	59,785	52,671	43,019	31,671	26,004	Depreciation Expense
125,644	121,738	128,002	94,217	80,776	86,461	90,948	126,047	161,249	109,034	57,481	40,006	192,761	102,583	95,144	93,510	64,362	Net Income, GAAP
13.35	10.95	10.5	11.83	24.54	19.29	21.66	25.13	21.3	24.35	34.74	33.33	20.63	21.37	4.57	4.79	15.91	Effective Tax Rate (%)
20.56	18.82	19.29	13.87	10.4	9.16	8.94	11.17	12.21	7.46	3.78	2.7	11.9	6.08	5.36	5.17	4.42	Profit Margin (%)
316,832	441,508	469,965	472,909	500,493	491,239	586,119	602,752	723,907	793,199	761,249	764,724	813,342	792,118	754,743	681,703	672,276	Working Capital
2,460	1,400	- -	- -	- -	18,500	24,100	86,000	140,250	115,339	70,212	49,656	51,029	32,622	3,402	167	- -	LT Debt
862,596	967,706	1,072,720	1,116,723	1,188,217	1,228,246	1,275,865	1,363,940	1,496,552	1,606,325	1,651,736	1,649,991	1,846,502	1,935,889	2,007,806	1,983,711	2,115,146	Total Equity
8.5	8.26	7.19	4.01	2.24	4	4.41	4.45	4.75	3.87	1.84	0.47	3.58	1.87	1.63	2.65	6.72	Return on Invested Capital (%)
18.99	16.01	14.61	9.54	7.53	7.46	7.3	9.21	10.51	6.67	3.48	2.69	11.07	5.57	5.03	4.64	6.58	Return on Capital (%)
19.82	16.22	14.75	9.59	7.56	7.6	7.55	9.83	11.53	7.22	3.68	2.54	11.55	5.65	4.95	4.71	6.57	Return on Common Equity (%)

Year	Q1	Q2	Q3	Q4	FY
2022	410,853	482,953	431,538	450,502	1,775,847
2023	443,048	495,722	483,063	- -	1,809,082
2024	444,593	528,312	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	201.36	452.61	99.77	- -	1,206.67
2023	281.9	115.24	260.95	- -	1,247
2024	169	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	329.47	0.09	- -	- -	330.75
2023	- -	- -	- -	- -	363.65
2024	427.31	- -	- -	- -	- -

Yuhan Corporation

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year